Genfit S.A. (NASDAQ:GNFT) Short Interest Up 6.0% in December

Genfit S.A. (NASDAQ:GNFT) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 63,400 shares, an increase of 6.0% from the December 15th total of 59,800 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 10,100 shares, the days-to-cover ratio is presently 6.3 days.

Genfit Price Performance

Shares of Genfit stock traded up $0.07 during midday trading on Monday, reaching $3.51. The company had a trading volume of 3,904 shares, compared to its average volume of 6,150. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. The stock has a fifty day simple moving average of $3.97 and a 200 day simple moving average of $4.49. Genfit has a 1-year low of $3.33 and a 1-year high of $6.42.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Genfit in a report on Friday, October 11th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.